Felsher DW - Search Results

1

MYC regulates the antitumor immune response through CD47 and PD-L1.

Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW. Casey SC, et al. Among authors: felsher dw. Science. 2016 Apr 8;352(6282):227-31. doi: 10.1126/science.aac9935. Epub 2016 Mar 10. Science. 2016. PMID: 26966191 Free PMC article.

2

Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Jain M, et al. Among authors: felsher dw. Science. 2002 Jul 5;297(5578):102-4. doi: 10.1126/science.1071489. Science. 2002. PMID: 12098700

3

Pharmacological inactivation of MYC for the treatment of cancer.

Felsher DW, Bradon N. Felsher DW, et al. Drug News Perspect. 2003 Jul-Aug;16(6):370-4. doi: 10.1358/dnp.2003.16.6.829309. Drug News Perspect. 2003. PMID: 12973448 Review.

4

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. Shachaf CM, et al. Among authors: felsher dw. Nature. 2004 Oct 28;431(7012):1112-7. doi: 10.1038/nature03043. Epub 2004 Oct 10. Nature. 2004. PMID: 15475948 Free article.

5

Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.

Shachaf CM, Felsher DW. Shachaf CM, et al. Among authors: felsher dw. Cancer Res. 2005 Jun 1;65(11):4471-4. doi: 10.1158/0008-5472.CAN-05-1172. Cancer Res. 2005. PMID: 15930260 Review.

6

CDK2 is required by MYC to induce apoptosis.

Deb-Basu D, Aleem E, Kaldis P, Felsher DW. Deb-Basu D, et al. Among authors: felsher dw. Cell Cycle. 2006 Jun;5(12):1342-7. doi: 10.4161/cc.5.12.2859. Epub 2006 Jun 15. Cell Cycle. 2006. PMID: 16760655

7

MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2.

Deb-Basu D, Karlsson A, Li Q, Dang CV, Felsher DW. Deb-Basu D, et al. Among authors: felsher dw. Cell Cycle. 2006 Jun;5(12):1348-55. doi: 10.4161/cc.5.12.2860. Epub 2006 Jun 15. Cell Cycle. 2006. PMID: 16760657

8

Conditional transgenic models define how MYC initiates and maintains tumorigenesis.

Arvanitis C, Felsher DW. Arvanitis C, et al. Among authors: felsher dw. Semin Cancer Biol. 2006 Aug;16(4):313-7. doi: 10.1016/j.semcancer.2006.07.012. Epub 2006 Jul 21. Semin Cancer Biol. 2006. PMID: 16935001 Review.

9

Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D, Robinson WH, Dill D, Nolan GP, Plevritis SK, Felsher DW. Shachaf CM, et al. Among authors: felsher dw. Cancer Res. 2008 Jul 1;68(13):5132-42. doi: 10.1158/0008-5472.CAN-07-6192. Cancer Res. 2008. PMID: 18593912 Free PMC article.

10

Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation.

Ney JT, Schmidt T, Kurts C, Zhou Q, Eckert D, Felsher DW, Schorle H, Knolle P, Tüting T, Barchet W, Büttner R, Limmer A, Gütgemann I. Ney JT, et al. Among authors: felsher dw. Hepatology. 2009 Feb;49(2):471-81. doi: 10.1002/hep.22652. Hepatology. 2009. PMID: 19105207

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

178 results

Search Page